Andrew M. Rogers - Concepedia

Concepedia

Author

Andrew M. Rogers

Harvard University

Also Known As

A M Rogers, A Rogers, A. M. Rogers, A. Michelle Rogers, A. Rogers, Andrew M. Rogers, Andrew Rogers

39

Publications

7.8K

Citations

16

H-Index

39

Concepts

All Affiliations

Harvard University Dana-Farber Cancer Institute Brigham and Women's Hospital Massachusetts General Hospital Center for Neuro-Oncology

AM

About

Andrew M. Rogers is an author at Harvard University specializing in medicine, tumor biology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	2.2K
2	Cell Biology	5	5	2K
3	Health Sciences	2	2	262
4	Immunology	2	2	675
5	Natural Sciences	1	1	12

Andrew M. Rogers

×

15

Publications

7.8K

Citations

14

H-Index

	Year	Citations
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Science	2007	4.4K
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Alexa B. Turke, Kreshnik Zejnullahu, Yi‐Long Wu, Cancer Cell Signal TransductionMet AmplificationMedicineMolecular BiologyEgfr Mutant Nsclc	2010	1.1K
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, Science Translational Medicine Cetuximab SensitivityOncologyErbb2 SignalingSignaling PathwayMedicine	2011	658
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors Dalia Ercan, Chunxiao Xu, Masahiko Yanagita, Cancer Discovery	2012	290
Noninvasive Detection of <i>EGFR</i> T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer Yanan Kuang, Andrew M. Rogers, Beow Y. Yeap, Clinical Cancer Research	2009	227
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor Dalia Ercan, Kreshnik Zejnullahu, Kimio Yonesaka, Oncogene Molecular PharmacologyTumor BiologyEgfr T790mCancer GrowthCell Biology	2010	225
A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening Pasi A. Jänne, Ana M. Borras, Yanan Kuang, Clinical Cancer Research	2006	218
Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors Jie Qi, Michele McTigue, Andrew M. Rogers, Cancer Research Molecular BiologyPharmacotherapyCancer BiologyDownstream Pi3kTumor Biology	2011	216
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients Jussi Koivunen, J. Kim, J. Lee, British Journal of Cancer	2008	165
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers Kimio Yonesaka, Kreshnik Zejnullahu, Neal I. Lindeman, Clinical Cancer Research	2008	119

Page 1